Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08SMN
|
||||
| Former ID |
DIB010935
|
||||
| Drug Name |
POP-1
|
||||
| Company |
Propanc Pty Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | Trypsin | Target Info | Modulator | [549592], [550162] | |
| Alpha-glucosidase | Target Info | Modulator | [549592], [550162] | ||
| Chymotrypsin | Target Info | Modulator | [549592], [550162] | ||
| WikiPathways | Activation of Matrix Metalloproteinases | ||||
| References | |||||
| Ref 549592 | US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. | ||||
| Ref 550162 | EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent). | ||||
| Ref 549592 | US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. | ||||
| Ref 550162 | EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.